Of central importance for the characterization and testing of Evobodies is a reproducible system in which the activity of Vg9Vd2 T cells against tumor cells can be measured. For this purpose, primary immune cells from peripheral blood of healthy donors are purified and the Vg9Vd2T effector cells therein are enriched and thoroughly characterized. In co-culture with tumor cell lines representing the cancer indication to be treated, the tumor cell killing activity of Vg9Vd2 T cells can be monitored under hundreds of different conditions, such as different Evobody variants at different concentrations or in combination with additional drugs. In addition, this assay is critical to ensure unaltered efficacy of Evobodies during humanization and sequence optimization, as well as to monitor reproducibility of different batches during cGMP production. This is a major step for Evobright’s own research and development capabilities, for its drug development program and for building new technologies in Austria.
We are very proud that Dr. Malte Deseke, an expert in T cells who previously conducted research with Prof. Dr. Immo Prinz, an internationally recognized specialist in T cells and head of the IKE Institute in Hamburg, will take over the management of Evobright’s screening laboratories from February 1, 2023.